Calabrese VP - Search Results

1

A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group.

Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE, Mamdani MB. Treiman DM, et al. Among authors: calabrese vp. N Engl J Med. 1998 Sep 17;339(12):792-8. doi: 10.1056/NEJM199809173391202. N Engl J Med. 1998. PMID: 9738086 Free article. Clinical Trial.

2

Reserpine action in Huntington's chorea.

Calabrese VP. Calabrese VP. N Engl J Med. 1973 Jul 12;289(2):104. doi: 10.1056/NEJM197307122890216. N Engl J Med. 1973. PMID: 4267988 No abstract available.

3

Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol.

Parra D, Beckey NP, Raval HS, Schnacky KR, Calabrese V, Coakley RW, Goodhope RC; Veterans Integrated Service Network 8 Pharmacy Benefits Management Utilization Committee. Parra D, et al. Am J Cardiol. 2005 Jun 15;95(12):1481-3. doi: 10.1016/j.amjcard.2005.02.019. Am J Cardiol. 2005. PMID: 15950578

4

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Parashos SA, et al. JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391. JAMA Neurol. 2014. PMID: 24711047 Free PMC article. Clinical Trial.

5

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

NINDS NET-PD Investigators. NINDS NET-PD Investigators. Clin Neuropharmacol. 2008 May-Jun;31(3):141-50. doi: 10.1097/WNF.0b013e3181342f32. Clin Neuropharmacol. 2008. PMID: 18520981 Free PMC article. Clinical Trial.

6

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Calabrese VP. Calabrese VP. Neurology. 2007 Jul 10;69(2):223-4; author reply 224. doi: 10.1212/01.wnl.0000271777.50910.73. Neurology. 2007. PMID: 17620562 No abstract available.

7

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL. Hutton JT, et al. Among authors: calabrese vp. Mov Disord. 2001 May;16(3):459-63. doi: 10.1002/mds.1085. Mov Disord. 2001. PMID: 11391739 Clinical Trial.

8

N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism.

Calabrese VP, Lloyd KA, Brancazio P, Cefali E, Martin P, Wall J Jr, Sica D. Calabrese VP, et al. Mov Disord. 1998 Sep;13(5):768-74. doi: 10.1002/mds.870130503. Mov Disord. 1998. PMID: 9756144

9

Vigilance performance in Parkinson's disease and depression.

Hart RP, Wade JB, Calabrese VP, Colenda CC. Hart RP, et al. Among authors: calabrese vp. J Clin Exp Neuropsychol. 1998 Feb;20(1):111-7. doi: 10.1076/1380-3395(199802)20:1;1-P;FT111. J Clin Exp Neuropsychol. 1998. PMID: 9672825

10

Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases.

Rawes JA, Calabrese VP, Khan OA, DeVries GH. Rawes JA, et al. Among authors: calabrese vp. Mult Scler. 1997 Dec;3(6):363-9. doi: 10.1177/135245859700300601. Mult Scler. 1997. PMID: 9493635

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page